Alteogen알테오젠
196170 · KOSDAQ · ₩196170 · 알테오젠
₩223,000▲ ₩4,500 (2.06%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- Securities registration statement정정신고서제출요구( 2026.10.19. 제출 증권신고서(합병) )Oct 28, 2026Open on DART
Predicted impact: Medium
Regulator asked for a corrected merger registration statement; deal size unknown, so likely a procedural delay.
- Amended: Securities registration statement[기재정정]증권신고서(합병)Oct 19, 2026Open on DART
Predicted impact: Low
- Securities Issuance Results (Voluntary Disclosure)증권발행결과(자율공시)Oct 14, 2026Open on DART
Predicted impact: Medium· Actual: −2.0% vs sector, volume 1.0× normal (5 trading days)
Securities issuance results; size not stated, but large market value limits impact.
- Securities Issuance Results (Voluntary Disclosure)증권발행결과(자율공시)Oct 14, 2026Open on DART
Predicted impact: Low· Actual: −2.0% vs sector, volume 1.0× normal (5 trading days)
Same securities issuance results repeated; lowered one level.
- Securities registration statement증권신고서(합병)Oct 14, 2026Open on DART
Predicted impact: Medium· Actual: −3.7% vs sector, volume 1.0× normal (5 trading days)
Merger registration statement; deal size vs Alteogen's large market value not given.
- Investor relations (IR) event기업설명회(IR)개최Oct 8, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Oct 6, 2026Open on DART
- Merger decision회사합병결정(종속회사의주요경영사항)Oct 6, 2026Open on DART
- Added attachment: Merger decision[첨부추가]주요사항보고서(회사합병결정)Oct 6, 2026Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Oct 6, 2026Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Oct 6, 2026Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Oct 6, 2026Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Oct 6, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Sep 21, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALT-B4 독점적 옵션·라이선스 계약 체결)Sep 2, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (ALT-B4 라이선스 계약 파트너사 MSD로부터 판매 마일스톤 수령 예정)Aug 31, 2026Open on DART
- New Facility Investment, etc.신규시설투자등Aug 21, 2026Open on DART
- Added attachment: Half-year report (Jun 2026)[첨부추가]반기보고서 (2026.06)Aug 14, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 13, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 13, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 13, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 13, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)Aug 7, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Aug 7, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALTB4 독점적 라이선스 계약 체결)Aug 5, 2026Open on DART
- Ex-Rights (Bonus Issue)권리락 (무상증자)Aug 4, 2026Open on DART
- Amended: Bonus share issue decision[기재정정]주요사항보고서(무상증자결정)Jul 20, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Jul 16, 2026Open on DART
- Trading halt주권매매거래정지 (무상증자)Jul 16, 2026Open on DART
- Other Key Management Matters (Tentative Suspension of Plan to Transfer Listing to KOSPI Market)기타주요경영사항 (유가증권시장 이전상장 추진 잠정 유보)Jul 16, 2026Open on DART
- Bonus share issue decision주요사항보고서(무상증자결정)Jul 16, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Jun 16, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (아이젠피주(ALT-L9, 아일리아 바이오시밀러) 식약처 품목허가 승인)May 15, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Preliminary earnings (consolidated)연결재무제표기준영업(잠정)실적(공정공시)May 8, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Apr 7, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Apr 7, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Apr 1, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 31, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (재조합 인간 히알루로니다제 제품 ALT-B4 독점적 라이선스 계약 체결)Mar 25, 2026Open on DART
- Audit report submitted감사보고서제출Mar 23, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 23, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 16, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 16, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 16, 2026Open on DART
- Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 27, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Feb 20, 2026Open on DART
- Cash dividend decision현금ㆍ현물배당결정Feb 11, 2026Open on DART
- Preliminary earnings영업(잠정)실적(공정공시)Feb 2, 2026Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (인간 히알루로니다제 제품(ALTB4) 독점적 라이선스 계약 체결)Jan 20, 2026Open on DART
Titles in Korean until English translations are added.
Also known as: Alteogen / 알테오젠 / 196170 / KRX:196170
Source: KRX statistical information